Literature DB >> 12142170

Management of thyroid cancer.

Louiza Vini1, Clive Harmer.   

Abstract

Thyroid cancers are a diverse group of malignant disorders ranging from indolent micropapillary carcinoma, which has no effect on life expectancy, to anaplastic tumours, which are invariably fatal even with aggressive treatment. Although the estimated incidence has increased by 14.6% over the past 40 years, the estimated death rate has fallen by 21%, probably as a result of earlier diagnosis. The natural history of thyroid tumours is no longer a mystery, and the prognostic factors identified can predict outcome fairly accurately. Improvements in management have mostly depended on information from large retrospective series, though there are still many areas open to debate. There has been, however, a general acceptance that thyroid cancer should be managed by multidisciplinary teams in specialised units following evidence-based guidelines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12142170     DOI: 10.1016/s1470-2045(02)00787-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  10 in total

1.  Preoperative determination of serum thyroglobulin to identify patients with differentiated thyroid cancer who may present recurrence without increased thyroglobulin.

Authors:  B Gibelli; P Tredici; C De Cicco; L Bodei; M T Sandri; G Renne; R Bruschini; N Tradati
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-04       Impact factor: 2.124

2.  Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma.

Authors:  Zeming Liu; Xiaoyu Li; Lan Shi; Yusufu Maimaiti; Tianwen Chen; Zhi Li; Shuntao Wang; Yiquan Xiong; Hui Guo; Wenshan He; Chunping Liu; Xiu Nie; Wen Zeng; Tao Huang
Journal:  Int J Clin Exp Med       Date:  2014-08-15

Review 3.  [Reoperation for thyroid cancer].

Authors:  H Vogelsang; T Brückner; K Scheidhauer; M Schwaiger; J R Siewert
Journal:  Chirurg       Date:  2005-03       Impact factor: 0.955

4.  Sonographic detection of thyroid cancer in breast cancer patients.

Authors:  Jeong Seon Park; Ki Keun Oh; Eun-Kyung Kim; Eun-Ju Son; Hang-Seok Chang; Soon Won Hong; Hee Jung Moon; Kyu Sung Kwack
Journal:  Yonsei Med J       Date:  2007-02-28       Impact factor: 2.759

5.  Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake.

Authors:  C A Fernández; M Puig-Domingo; F Lomeña; M Estorch; V Camacho Martí; A L Bittini; M Marazuela; J Santamaría; J Castro; P Martínez de Icaya; I Moraga; T Martín; A Megía; M Porta; D Mauricio; I Halperin
Journal:  J Endocrinol Invest       Date:  2009-03       Impact factor: 4.256

6.  Anti-apoptotic effects of protein kinase C-delta and c-fos in cisplatin-treated thyroid cells.

Authors:  Antonella Muscella; Loredana Urso; Nadia Calabriso; Carla Vetrugno; Alessio Rochira; Carlo Storelli; Santo Marsigliante
Journal:  Br J Pharmacol       Date:  2009-02-27       Impact factor: 8.739

7.  Thyroid carcinoma with bone metastases: a prognostic factor study.

Authors:  Karl Wu; Shen-Mou Hou; Tien-Shang Huang; Rong-Sen Yang
Journal:  Clin Med Oncol       Date:  2008-02-09

8.  The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progression.

Authors:  A Ferru; G Fromont; H Gibelin; J Guilhot; F Savagner; J M Tourani; J L Kraimps; C J Larsen; L Karayan-Tapon
Journal:  Br J Cancer       Date:  2006-11-21       Impact factor: 7.640

9.  Usefulness of Stereotactic Radiotherapy Using CyberKnife for Recurrent Lymph Node Metastasis of Differentiated Thyroid Cancer.

Authors:  Joji Kawabe; Shigeaki Higashiyama; Mitsuharu Sougawa; Atsushi Yoshida; Kohei Kotani; Susumu Shiomi
Journal:  Case Rep Endocrinol       Date:  2017-03-15

10.  A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.

Authors:  Maria E Cabanillas; Martin Schlumberger; Barbara Jarzab; Renato G Martins; Furio Pacini; Bruce Robinson; Judith C McCaffrey; Manisha H Shah; Donald L Bodenner; Duncan Topliss; Corina Andresen; James P O'Brien; Min Ren; Yasuhiro Funahashi; Roger Allison; Rossella Elisei; Kate Newbold; Lisa F Licitra; Steven I Sherman; Douglas W Ball
Journal:  Cancer       Date:  2015-04-24       Impact factor: 6.860

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.